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Abstract
Despite the scarcity of high quality cancer registries and lack of reliable mortality data, it is clear
that human papillomavirus (HPV)-associated diseases, particularly cervical cancer, are major
causes of morbidity and mortality in sub-Saharan Africa (SSA). Cervical cancer incidence rates in
SSA are the highest in the world and the disease is the most common cause of cancer death among
women in the region. The high incidence of cervical cancer is a consequence of the inability of
most countries to either initiate or sustain cervical cancer prevention services. In addition, it
appears that the prevalence of HPV in women with normal cytology is higher than in more
developed areas of the world, at an average of 24%. There is, however, significant regional
variation in SSA, with the highest incidence of HPV infection and cervical cancer found in
Eastern and Western Africa. It is expected that, due to aging and growth of the population, but
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also to lack of access to appropriate prevention services and the concomitant human
immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic, cervical
cancer incidence and mortality rates in SSA will rise over the next 20 years. HPV16 and 18 are the
most common genotypes in cervical cancer in SSA, although other carcinogenic HPV types, such
as HPV45 and 35, are also relatively more frequent compared with other world regions. Data on
other HPV-related anogenital cancers including those of the vulva, vagina, anus, and penis, are
limited. Genital warts are common and associated with HPV types 6 and 11. HIV infection
increases incidence and prevalence of all HPV-associated diseases. Sociocultural determinants of
HPV-related disease, as well as the impact of forces that result in social destabilization, demand
further study. Strategies to reduce the excessive burden of HPV-related diseases in SSA include
age-appropriate prophylactic HPV vaccination, cervical cancer prevention services for women of
the reproductive ages, and control of HIV/AIDS.
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1. Introduction
While communicable diseases, such as tuberculosis and human immunodeficiency virus
(HIV)/acquired immunodeficiency syndrome (AIDS), maternal mortality and malaria,
receive the most attention in terms of the burden of disease in Africa, cancer is largely
under-recognized as a significant health problem. Yet, the burden of cancer is increasing in
sub-Saharan Africa (SSA) [1]. In 2008, it was estimated that there were 551,221 new cancer
cases and 420,978 deaths in SSA [2]. These numbers are estimated to double in the next 20
years due to aging and growth of the overall population. The data from the GLOBOCAN
2008 database of the International Agency for Research on Cancer (IARC, Lyon, France)
present estimates of the incidence of, and mortality from, 27 major cancers in 184 countries
or territories in 2008 [2]. Invasive cervical cancer (ICC) is the most common cancer
diagnosed in women in SSA, with 75,141 new cases reported per year, and also the leading
cause of cancer death at 50,233 deaths [2]. Rates of cervical cancer vary considerably in
different sub-regions; however, cervical cancer ranks first or second (after breast cancer) in
all individual SSA countries and sub-regions. Guinea, Zambia, Tanzania, Malawi, and
Mozambique have some of the highest ICC incidence rates in the world at >50/100,000
women. Of note, the rate of cervical cancer in the United States of America (USA) between
1947 and 1949, prior to the introduction of the Pap smear in the 1960s, was 40/100,000 in
white women and 73/100,000 in black women [1]. In contrast, breast cancer is the most
frequent cancer in women inmore developed countries. In several SSA countries, breast
cancer has now also become the most common cancer in women, which is a shift from
earlier decades when cervical cancer was more common than breast cancer.
The aim of this report is to review the data on the burden of human papillomavirus (HPV)
and HPV-related diseases in SSA countries, including: (Middle Africa) Angola, Cameroon,
Central African Republic, Chad, Congo, Democratic Republic of Congo, Equatorial Guinea,
Gabon, Säo Tomé and Principe; (Western Africa) Benin, Burkina Faso, Cape Verde, Côte
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d’Ivoire, Gambia, Ghana, Guinea, Guinea Bissau, Liberia, Mali, Mauritania, Niger, Nigeria,
Saint Helena, Senegal, Sierra Leone, Togo; (Eastern Africa) Burundi, Comoros, Djibouti,
Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mayotte, Mozambique, Réunion,
Rwanda, Seychelles, Somalia, South Sudan, Sudan, Uganda, United Republic of Tanzania,
Zambia, Zimbabwe; (Southern Africa) Botswana, Lesotho, Namibia, South Africa,
Swaziland. Other important factors related to HPV and HPV-related diseases, such as the
ongoing HIV epidemic and sociocultural determinants in the region are also reviewed.
2. Burden of cervical cancer in sub-Saharan Africa
2.1. Cancer registration in the region: data sources and methods
Geographical variations in cervical cancer incidence and mortality in SSA countries,
information on age-specific incidence curves, survival, temporal trends, projections and an
analysis on years of life lost (YLL) are presented in this section.
Country-specific GLOBOCAN 2008 estimations were used [2]. The country-specific cancer
incidence and mortality rates for SSA were based on data reported by four national cancer
registries (The Gambia, Namibia, Botswana, Swaziland) and some 40 local cancer registries.
Although the national registries provided national data, they were still based on relatively
low quality registration procedures and none were of sufficient quality to be included in the
most recent volume of the IARC Cancer Incidence in Five Continents (CI5) [3]. The local
registries generally covered major cities and were predominantly urban. Only two registries
from Africa, (Kampala, Uganda and Harare, Zimbabwe) were included in CI5 vol. IX [3].
Fig. 1 shows the data sources used by GLOBOCAN to estimate cancer incidence in 2008 for
SSA. No reliable cancer-specific mortality statistics are available in any SSA countries, and
mortality in GLOBOCAN was estimated by combining corresponding estimates of cancer
incidence with country-specific survival probabilities [2]. Incidence and mortality rates are
presented as age-standardized rates (ASR), calculated using the weights of the “world
standard” population [1–3].
The IARC CI5 was used for information on temporal trends, and GLOBOCAN was used for
projections of ICC incidence from 2008 to 2030. The projections assume that estimated rates
in 2008 would be retained until 2030, with the forecasted population projections in 2030
applied to the age-specific rates in a given region or country. YLL were estimated by
multiplying, for all world regions, the number of cancer-specific deaths at a given age by the
standard life expectancy for age group. Mortality by age groups was derived from
GLOBOCAN 2008. A standard female life expectancy scale, starting with 82.5 years at
birth was used for all regions, i.e., the life expectancy for Japan, the highest observed in the
world.
2.2. Incidence and mortality
SSA is the region with the highest incidence of ICC worldwide [1–3]. Although the region
was home to an estimated 9% of the world female population >15 years of age in 2008, 14%
of the world’s incident ICC (75,141 cases each year) and 18% of the world’s ICC deaths
(50,233) occurred in SSA. For an average woman in SSA, the cumulative ICC incidence and
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mortality risk (0–74 years) are 3.5% and 2.7%, respectively. The mortality risk is about 70%
higher than in South-Central Asia (1.6%), the region with the second highest cumulative
mortality rates worldwide. The overall ICC age-standardized incidence and mortality rates
(ASIR and ASMR) for SSA are 31.7 and 22.5 per 100,000 women, compared with 9.1 and
3.1, respectively, in more developed countries. Within the SSA region, estimated ASIR and
ASMR are highest in Eastern and Western Africa with ASIR of 34.5 and 33.7 per 100,000
women, respectively, and ASMR of 25.3 and 24.0 per 100,000 women, respectively (Table
1 and Figs. 2 and 3). Not surprisingly, ICC is the most important cause for cancer death in
women in Eastern, Western and Middle Africa and second most important cause after breast
cancer in Southern Africa. The burden of ICC is highest in Guinea, Zambia, Tanzania,
Malawi and Mozambique with ASIRs greater than 50/100,000 women (Supplementary
Table 1).
In Fig. 4, age-specific ICC incidence rates by SSA sub-regions and less or more developed
world regions are compared. In all SSA subregions, ASIRs rise by the age of 40–44
(36/100,000 and more) and reach a peak around the age of 55–65 years. This is similar but at
a higher level, than what is seen in less developed world regions in general. Conversely,
age-specific incidence is relatively lower in more developed countries, with a maximal rate
(20/100,000) at around 40 years of age that does not further increase. This is best explained
by the effect of cervical cancer screening programs that stop the onset of cervical cancer in
more developed countries, compared with most countries in the developing world, including
SSA, which do not have national cervical cancer screening programs.
2.3. Survival
Cancer survival is related to the quality of early diagnosis, treatment and clinical follow-up
care in any given setting. One study reliably assessed 5-year relative survival rates for
women with ICC (5-year survival of women diagnosed with ICC, divided by the expected 5-
year survival derived from similar women from the general population) in three cancer
registries in The Gambia, Uganda, and Zimbabwe for women registered with ICC between
1993 and 1997, and also in other countries from Asia and Central America [4]. Age-
standardized relative survival (ASRS) after ICC diagnosis was the lowest in SSA, compared
with other regions: 23% in The Gambia, 19% in Uganda, 44% in black populations and 61%
in white populations in Zimbabwe. In comparison, ASRS exceeded 75% in Hong Kong and
South Korea, and 65% in Singapore. The three selected countries were the only ones in the
region that fulfilled the inclusion criteria in terms of sustained reliable cancer data
registration for this study. Therefore, it is quite likely that the survival rates in many SSA
countries that were not included here would be even lower than those reported in this study.
Striking differences in cancer survival between countries, or between distinct populations
within a country, reflect the large inequality in accessible and available cancer health
services for populations across the world. These poor survival rates emphasize the
importance and urgent need for improvement of health services in SSA countries.
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Ten-year trends for ASIR were compared between 1987–1989 and 1994–1996 in Bamako,
Mali; between 1991–1993 and 1998–2002 in Kyadondo, Uganda; and between 1990–1992
and 1998–2002 in Harare, Zimbabwe (Table 2).
Trends in ASIR in SSA are not favorable. Increases were observed in Mali (23 to
36/100,000 over time), and Uganda (41 to 46/100,000). However, a decrease was observed
in Zimbabwe (65 to 48/100,000). The impact of HIV on trends in ICC incidence is not clear,
as both Uganda and Zimbabwe had a highly elevated HIV prevalence among the general
population in the nineties, and show opposite trends for cervical cancer over time. Parkin
DM et al. [5] reported more details on cancer incidence trends in Kampala between 1991
and 2006. They noted a general increase in cancers linked to Western lifestyles, such as
breast cancer (4.5% increase annually), although cancers not linked to western lifestyles,
such as stomach, liver, esophagus and cervical cancers, did not decrease over time. In fact,
cervical cancer ASIR increased to 52/100,000 women for the period 2002–2006. This
increase was unlikely to be related to the HIV epidemic, as most of the increase was seen in
older (postmenopausal) women.
2.5. Projections
If the 2008 cancer incidence rates are applied to the projected demographic evolution
between 2008 and 2030, namely increasing numbers and aging populations, an estimated
139,558 new cases of ICC will be diagnosed in 2030 in SSA. This is a 90% increase in most
of the SSA sub-regions (Fig. 5), except in Southern Africa where the increase would be
around 35%. The relatively weaker increase in Southern Africa is a result of a lower
projected population increase, mainly due to the rampant HIV epidemic in this sub-region
[6]. An increase in the number of new cases of ICC in SSA could only be avoided if the
ASIR were to decrease by 2% yearly, which would be hugely challenging, given the current
lack of organized cervical cancer screening in the region. A larger increase in cervical
cancer may also be recorded if an increasing number of HIV-positive women reach the age
when cervical cancer starts being common or other risk factors for the disease (e.g., sexual
behaviour) increase.
2.6. Years of life lost
ICC was estimated to be responsible for 1,474,208 YLL in women aged 15 years or more in
the SSA region. It was the most important cause (20%) of YLL due to cancer in women in
the region, and represented 19% of all YLL due to ICC worldwide (Fig. 6).
3. Cervical HPV infection and type distribution in sub-Saharan Africa
3.1. Methods of the literature review
The data presented on HPV prevalence in the cervix are based on literature updates of meta-
analyses by Bruni L and colleagues on HPV in women with normal cytology [7] and by Li
N and colleagues [8] on HPV in women with ICC. The literature search was updated to
December 2011. Studies were eligible for inclusion if they reported on more than 100
women with normal cytology or 20 women with ICC, and used DNA polymerase chain
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reaction (PCR)-based assays or Hybrid Capture® 2 (HC2), Qiagen Gaithersburg, Inc., MD,
USA (previously Digene Corp.) techniques for HPV detection. A Medline search was
performed using the keywords “HPV” and individual names of SSA countries. References
cited in retrieved articles were also evaluated and included if appropriate. Studies were
excluded if they reported on special populations (pregnant, HIV-positive, or women with a
previous diagnosis of cervical lesion). For specific information on the HIV population and
HPV please see Denny L et al,. Vaccine 2012 [9]. One study from Sudan including 94
women with normal cytology was also included because of the scarcity of data available
from this area.
3.2. HPV prevalence in women with normal cytology
Twenty-three studies matched the above criteria and were included in this overview,
presented in Table 3. The different subregions were fairly well represented, except for
Middle Africa, with only one study from the Democratic Republic of Congo. HPV
prevalence ranged between 3.2% in Sudan [10] and 47.9% in Guinea [11]. Although the
reason for this is not very clear, this wide distribution could be explained by methodological
differences between the studies, resulting in inclusion of study populations that show
different risk for the presence of HPV, such as age or sexual behaviour. The most common
HPV type detected in a majority (11/15) of studies that performed DNA typing was HPV16,
with a prevalence range of 1.0–7.5%.
In Western Africa, studies reported HPV prevalence for a total of 6,212 women with normal
cytology (Table 3). The highest prevalence of HPV (any type) was found in Guinea, where
360/752 (47.9%) women were HPV-positive using PCR technology [11]. Further, HPV16
was the most common type identified in women with normal cytology at 6.6%, followed by
HPV45 (4.7%), 52 (4.0%) and 18, 35 and 58 (3.2% each). The lowest HPV prevalence was
found in a Nigerian study of 1,075 women, of whom 113 (10.5%) were high-risk (hr) HPV
positive [12]. Of the three studies carried out in Nigeria, the range of HPV detection in
women with normal cytology was 10.5–18.8% for the two studies that reported on hrHPV
and 24.8% for the study that reported on a wider spectrum of HPV types [12–14].
The highest prevalences of HPV detected in women with normal cytology were found in
Eastern Africa. HPV prevalences ranged from 3.2% (3/94) in Sudan [10] to 41.4% (84/203)
in Mozambique [15].
In Southern Africa, data were only available from studies in Cape Town, South Africa. The
range of HPV prevalence among women with normal cytology ranged from 15.5%
(197/1,269) hrHPV [16], to 20.4% (173/848) hrHPV [17].
The only study in Middle Africa from the Democratic Republic of Congo reported one of
the lowest hrHPV positivities (8.7%, 99/1,138) [18].
The meta-analysis by Bruni L et al. [7] reported on HPV type distribution among one
million women with normal cytology worldwide, including 7,705 women from Africa. The
HPV prevalences reported in this study were adjusted for geographical sub-region, women’s
age, study year, HPV testing method, proportion of high-risk and low-risk (LR) HPV tested,
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and clusters. Adjusted HPV prevalences among SSA women were estimated at 33.6%,
19.6% and 17.4% in Eastern, Western and Southern Africa, respectively. By comparison,
the overall estimate was 16.1% for Latin America and the Caribbean, 14.2% for Europe and
11.7% worldwide. Globally, 22.5% of HPV infections were attributed to HPV16. In SSA,
HPV16 infections were found in lower percentages (13.7%, 11.3% and 11.1% for Southern,
Eastern and Western Africa, respectively), but HPV16 was still the most common type
identified [7].
3.3. HPV type distribution in invasive cervical cancers
Twenty-four studies matched the above criteria and were included in the review (Table 4).
No studies were identified from Middle Africa, but the other sub-regions were fairly well
represented with 478 cases from Western Africa, 1,516 from Eastern Africa and 360 from
Southern Africa. The most common HPV type detected in HPV-positive ICC among studies
using broad-spectrum DNA PCR tests was HPV16, ranging from 38.5% in Mali [19] to
81.8% in Tanzania [20]. In most of the studies, HPV18 and 45 were the second and third
most frequent HPV types identified. The HPV16 and/or 18 relative contribution in ICC,
when reported, ranged from 56.4% [21] to 91.5% [22]. In almost half of the studies in which
information on HPV35 was reported, this type was the fourth in the ranking before HPV
types 31 and 33.
We mention here results of two large studies from the region among women with ICC that
are not published to date, but were reported at international conferences. One recent
multicenter study from Uganda reported on HPV type distribution in 379 HIV-negative and
107 HIV-positive women with ICC [23]. Eighty-four percent of cases (HIV-positive and
HIV-negative) were HPV-positive, and the most common HPV types were HPV16 (49%),
HPV18 (23%), HPV45 (13%), and HPV35 (5%). Another study by Schmidt J et al. [24]
reported recently on HPV type distribution in women with ICC from South Africa, Ghana
and Nigeria. Biopsy specimens were collected from 570 women from October 2007 to
March 2010. A total of 93.7% of women were HPV-positive and 86.8% were infected with a
single type. In those women infected with one HPV type, the most common types in women
with squamous cell carcinoma (n = 447) were HPV16 (51.2%), HPV18 (15%), HPV35
(8.7%), HPV45 (7.4%). In women with adenocarcinoma (n = 27), HPV18 (29.6%) was the
most common, followed by HPV16 (22.2%), HPV45 (18.5%) and HPV35 (3.7%).
In the recent meta-analysis by Guan P et al. [25], which included 2,402 HPV-positive cases
of ICC from Africa, the most common HPV type was HPV16 (53.1% of HPV-positive ICC),
followed by HPV18 (19.8%), HPV45 (11.0%), and HPV35 (4.9%). The same study
calculated oncogenic potential of different types by comparing the prevalence of specific
types in women positive for HPV over the disease spectrum. For instance, HPV35 was well
represented in HPV-positive women with normal cytology (6.6%) and with either low-grade
(7.9%) or high-grade (11.8%) cervical cancer precursors [25]. However, HPV35 was poorly
represented in invasive cancers (4.9%) suggesting that its oncogenic potential is less than
that of HPV16 or 18, which were relatively better represented in invasive cancer, compared
with normal women or cancer precursors. The same was true for the types 31, 52 and 58, all
very frequent in women with normal cytology, but less frequent in invasive cancer. The
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prevalence of HPV45 was higher in HPV-positive ICC in Africa (11.0%), compared to other
regions (3.0% in Eastern Asia to 6.1% in South/Central America), and was also increased in
ICC, compared to HPV-positive women with normal cytology (5.9%) in Africa [25].
Another study evaluated the results of HPV DNA testing on 10,575 ICC biopsies from 38
countries worldwide, of which 8,977 (85%) were positive for HPV [26]. Of the 691 cases
from Africa, 544 (79%) were HPV-positive; of these, 443 (81%) contained a single or
undetermined HPV infection and 101 (19%) had multiple types, which was the highest
proportion for all regions (range 4% in North America to 11% in Oceania). This study
confirmed that HPV16 is the most frequent type in ICC in Africa (48% among HPV-positive
results), followed by HPV18 (23%), HPV45 (10%), and HPV35 (5%).
de Sanjosé S et al. [26] reported that multiple infections were most commonly found in
SSA, however like in our review of the literature there was, in SSA, a wide regional
variation of infection with multiple types from 2% in Ethiopia [27] and South Africa [28] to
34% in Mozambique [29]. A fraction of this high number of multiple infections may be due
to undiagnosed or unknown concurrent HIV infection. An increase in the proportion of
multiple infections with HPV is well described in HIV-positive women, up to 10-fold
compared with HIV-negative women with ICC (Denny L et al. Vaccine 2012 [9]).
4. Other anogenital cancers in sub-Saharan Africa
4.1. Methods of the literature review
Methods and data sources used in this section include: the IARC CI5 for retrieving the
incidence of vulvar, vaginal, anal, and penile cancers in sub-Saharan African cancer
registries [3]; HPV information for these anatomical sites was retrieved through a similar
literature search as described in section 3, however including men where appropriate, and
without sample size limitations.
4.2. Burden of vulvar, vaginal, anal and penile cancers
All of these cancers are rare, as evidenced by their very small numbers and low incidence,
reflected in cancer registry data from Uganda and Zimbabwe (Table 5). Penile cancer is also
a rare tumour in developed countries but more common in South America and East Africa
[3]. Although studies on the prevalence of HPV in vulvar, vaginal or anal cancers in SSA
were not found, there is an increasing body of evidence from other parts of the globe
strongly linking HPV DNA with cancers and pre-cancers of the anus, vulva, vagina, and
penis [30–32].
4.3. HPV prevalence in men
Specimens from the genital and perianal regions of Kenyan men from the fishing industry
revealed an HPV positivity rate of 57.6% [33]. Table 6 shows the HPV type distribution and
HPV tests performed in various studies in men in the SSA region. HPV analysis of
specimens from similar anatomic regions (except perianal) of uncircumcised HIV-negative
Kenyan men (recruited from various workplaces, community organizations and sexually
transmitted infection [STI] clinics) revealed HPV presence in 51.1% [34]. HIV-negative
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men recruited into male circumcision trials in Uganda showed varying presence of hrHPV
infection depending on whether they were assessed at baseline (37.6%) [35], uncircumcised
and assessed at 1-year follow-up (36.3%), or circumcised recruits and assessed at 1-year
follow-up (21.5%) [36]. Male recruits from a circumcision trial in South Africa showed
similar trends in differences of HPV positivity between uncircumcised and circumcised
males, with hrHPV prevalence of 23.2% and 14.0%, respectively [37].Moreover, male
circumcision has also been shown to result in reduction of HPV infections in the female
partners of HIV-negative men [38].
4.4. HPV prevalence in penile carcinoma
The prevalence of HPV DNA in penile carcinoma ranges between 20% and 80%, but varies
depending on the methods utilized for detection, and geographical variability [39–42]. In
small case studies of penile carcinoma from Uganda [43] and Kenya [44], HPV DNA was
present in 64.7% and 68.2% of cases, respectively.
5. Clinical burden of genital warts in sub-Saharan Africa
5.1. Methods of the literature review
A Medline literature search was performed for studies reporting on prevalence and incidence
of genital warts (GW) in SSA, published before January 2012. Keywords were used in the
following search string: “Genital warts” OR “HPV” AND “Africa”. References cited in
retrieved articles were also evaluated and included if appropriate.
5.2. Prevalence and incidence of genital warts in SSA
GW have been recognised as a common sexually transmitted disease in SSA for many years.
Latif AS [45] described 929 patients at a sexually transmitted disease clinic in Harare,
Zimbabwe in 1980 and recorded prevalences of GW of 1.9% in men and 0.4% in women.
Schmauz R and Owor R [46] studied GW in Uganda during the period 1964–1975 and
provided clinical, pathological, and ecological evidence for a link between GW and cervical,
vulvar, vaginal, and penile cancers.
As elsewhere, GW in Africa are most commonly associated with HPV6 or 11 [47].
Population-based data for GW incidence or prevalence in Africa are limited. Some data
approximating this are available from recent large-scale phase 3 trials. MDP301 was a
randomized controlled trial of PRO2000 vaginal microbicide gel in 9,385 women in South
Africa, Tanzania, Uganda, and Zambia [48]. Women were selected as HIV-negative and
non-pregnant at entry and had a mean age of 30 years. Over 8,079 women-years of follow-
up, an incidence of GW of 0.4 per 100 women-years was recorded (Sheena McCormack,
Imperial College, London, personal communication, December 2011), and this was in the
presence of condom promotion and the potential anti-HPV activity of the polyanionic
microbicide.
In SSA, the epidemiology of GW and genital HPV is inextricably interwoven with that of
HIV infection. Low AJ and colleagues [49] performed a prospective study with median
follow-up of 1.7 years in 765 high-risk women in Burkina Faso. At entry, mean age was 28
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years and HIV-1 prevalence was 35.6%. GW prevalence at baseline was 1.6% among HIV-
negative women and 7.0% among HIV-positive women. During follow-up, GW incidence
was 1.1 per 100 women-years among HIV-negative women, 7.4 per 100 women-years
among HIV-positive women with a CD4+ lymphocyte nadir >200 cells, and 14.6 per 100
women-years among HIV-positive women with a CD4+ nadir <200 cells. Antiretroviral
therapy was not protective against incident or persistent GW. Detection of HPV6 DNA and
abnormal cervical cytology were strongly associated with incident GW.
The results of the Australian HPV vaccine program have shown that the most effective
single strategy for significant control of GW disease burden in SSA would be population-
based implementation of quadrivalent HPV vaccination [50].
6. Impact of the HIV epidemic on HPV-related disease
For this section, a Medline literature search was performed on the topics of HPV and
cervical cancer, HIV/AIDS, and studies from SSA region. A commentary on the underlying
context along with the limited evidence to date on this topic from the SSA region is
presented in this section (the interaction between HIV and HPV is described in greater detail
elsewhere in this issue, Denny L et al. Vaccine, 2012 [9]).
The HIV/AIDS epidemic has negatively impacted health and development in many
developing regions of the world, particularly in countries in SSA. HIV-infected individuals
progressively develop opportunistic infections and AIDS-associated malignancies with
deteriorating immune status, unless corrected by combination antiretroviral therapy (cART).
HPV shares the sexual mode of transmission with HIV, although the former is more easily
transmitted or acquired than the latter. Indeed, populations of both men and women who
acquire HIV through sexual transmission have been shown to have a substantially higher
prevalence of cervical/anal HPV infection (presumably also acquired sexually) than HIV-
uninfected individuals. Observational studies have shown that HIV-infected women have a
higher risk of incidence and progression and lower likelihood of regression of cervical
intraepithelial neoplasia (CIN) compared with HIV-uninfected women. Similar trends in risk
are also observed for increasing prevalence of anal HPV infection and anal intraepithelial
neoplasia (AIN) in HIV-infected men who have sex with men (MSM) [51] and HIV-infected
women reporting history of anal sexual intercourse [52].
In addition, there is now some evidence that HPV infection may increase the probability of
HIV acquisition. In a Kenyan male circumcision trial, it was found that the hazard ratio for
incident HIV infection among men with HPV-positive glans/coronal sulcus specimens was
1.8 (95% CI, 1.1–2.9), compared with men with HPV-negative glans/coronal sulcus
specimens, after controlling for subsequent circumcision status, baseline herpes simplex
virus type 2 serostatus, and sexual and sociodemographic risk factors [53]. Zimbabwean
women with cervical low-risk HPV infection were also 1.7 times more likely to acquire HIV
infection [54].
It has been shown that multiple HPV types are very common in precancerous lesions in
HIV-infected populations [30,55]. HPV type 16 is the most common genotype, as in HIV-
uninfected populations, although the relative proportion of HPV16 compared to other
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carcinogenic HPV types is influenced by the degree of immunosuppression [28,56,57]. In
addition to a wider variety and multiplicity of carcinogenic HPV types, HIV-infected
individuals also have a high prevalence of non-carcinogenic HPV types, or HPV types with
unknown carcinogenicity [58].While these types are almost always present along with
concurrent HPV types in cervical/anal precancerous lesions, their etiologic significance is
still unknown [58].
cART has only recently been implemented in SSA with variable coverage. In 2010, it was
estimated by UNAIDS that 49% of people needing cART (CD4 ≤350 cells/µL) in SSA had
access to treatment [59]. In developing countries, before the widespread availability of
cART, HIV-infected individuals often did not live long enough for precancerous lesions to
progress to cancer [60,61]. If true that cART has a limited or no impact on reducing
cervical/anal cancer incidence rates [62] (although this is controversial with conflicting
reports in the literature), HIV-infected individuals who live longer on cART may be at
increased risk of persistent HPV infection and precancerous CIN/AIN progressing to
cervical/anal cancers respectively, unless effective screening and early treatment measures
are put in place [63,64]. However, it is important to note that screening the anus for
precancerous lesions and treating those detected has not yet been shown to prevent
progression to anal cancer, as it has been shown with the detection and treatment of cervical
cancer precursors. Recent observational evidence has also pointed to the importance of the
level of adherence to cART as influencing the natural course (progression or regression) of
cervical neoplastic disease [65].
7. Sociocultural determinants of HPV-related disease
For this section, a Medline literature search was performed on the topics of HPV, polygamy,
armed conflict, violence, rape, and forced migration. Limited evidence for the SSA region
was found and is presented below.
7.1. Culture of sex and marriage in SSA and its role in HPV-related disease: Patterns of
sexual behaviour and sexual networks (polygamy, multiple concurrent partnerships, core
groups)
Country-specific epidemiologic data for the SSA region are relatively sparse. However, the
available data suggest that HPV infection is more common among women in SSA than
among women in Asia, Europe, or the Americas, as described earlier in this chapter. Marked
regional differences in HPV prevalence suggest that a complex array of social, cultural, and
structural factors act to increase SSA women’s risk of HPV infection and HPV-related
disease.
Our English language literature search did not yield any qualitative or quantitative studies
that specifically address sociocultural factors, such as concurrency, polygamy, or religious
beliefs, associated with women’s risk of HPV infection in SSA. However, several parallels
may be drawn from the wide body of literature on HIV and other STIs. It is well established
that risky sexual behaviours, including early sexual debut and having unsafe sex with
multiple partners, increase women’s risk of STIs, contributing substantially to the ongoing
HIV epidemic in the region. Although concurrent sexual relationships, including
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polygamous marriage, may increase women’s risk of STIs [66], this theory is not wholly
supported by empirical findings and may apply differently to different STIs [67,68].
Therefore, health messaging and behavioural interventions that effectively reduce multiple
partnerships, regardless of whether those partnerships overlap in time, continue to be an
important yet elusive public health goal.
7.2. Social destabilization, armed conflict, violence against women, and their impact on
HPV-related disease
Even in normal circumstances, accessibility of health services in SSA is hampered by the
scarcity of subsidized care, and requires substantial cost contribution by individuals and
families. In addition, vast areas of West Africa, the Great Lakes Region, and the Horn of
Africa have recently experienced or are currently experiencing protracted armed conflict.
Here, as in other parts of the world, war and unrest have had devastating effects on health
and development [69]. Health systems, disease control programs, and reproductive health
services in Africa’s conflict-affected areas have been disrupted [70].War and unrest also
have had profoundly destabilizing effects on human resources for health [71]. As a result,
access to health services is severely limited for internally displaced persons and refugees in
SSA.
More than limiting access to health services, war and unrest also commonly result in
systematic and horrific acts of violence against women and girls [72]. Although there are
innumerable examples and reports of escalating gender-based violence during armed
conflicts—with rape increasingly used as a weapon of war across Africa [73]—there have
been no epidemiologic studies examining whether women in conflict-affected areas face a
higher burden of HPV infection and HPV-associated disease.
Nevertheless, it is abundantly evident that men, women, and children in conflict-affected
areas worldwide face severely restricted access to essential health and social services. Future
guidance and policy on humanitarian assistance should continue to promote minimum
standards for health care, including expanded reproductive health services [74].
Development of equitable and sustainable national plans for comprehensive health services,
including cancer prevention, screening, and treatment, should be a priority during post-
conflict reconstruction of health systems.
8. Conclusion
HPV-associated diseases, particularly cervical cancer, are major causes of morbidity and
mortality in SSA. Cervical cancer incidence rates in SSA are the highest in the world and the
disease is the most common cause of cancer death among women in the region. It is
expected that due to lack of access to appropriate prevention services and the concomitant
HIV/AIDS epidemic, cervical cancer incidence and mortality rates in SSA will rise over the
next 20 years. HPV16 and HPV18 are the most common genotypes in cervical cancer in
SSA, although other carcinogenic HPV types are also relatively more frequent compared to
other world regions. Even in women with normal cervical cytology in SSA, at least one in
five are infected with carcinogenic HPV genotypes. Data on other HPV-related anogenital
cancers including those of the vulva, vagina, anus, penis and head and neck cancers are
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limited. GW are common and associated with HPV types 6 and 11. HIV infection increases
incidence and prevalence of all HPV-associated diseases. Sociocultural determinants of
HPV-related disease, as well as the impact of forces that result in social destabilization,
demand further study. Strategies to reduce the excessive burden of HPV-related diseases in
SSA include age-appropriate prophylactic HPV vaccination, cervical cancer prevention
services for women of the reproductive ages, control of HIV/AIDS, and health promotion
strategies such as sexual education and lifestyle modification.
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Methods of estimation for GLOBOCAN 2008 cancer incidence data for the sub-Saharan
Africa region. Adapted from Jemal A et al. [1].
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Age-standardized incidence rates of cervical cancer in sub-Saharan Africa region. Adapted
from GLOBOCAN 2008 [2]. ASR: Age-standardized incidence rate, per 100,000 women
and year (all ages).
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Age-standardized mortality rates of cervical cancer in sub-Saharan Africa region. Adapted
from GLOBOCAN 2008 [2]. ASR: Age-standardized mortality rate, per 100,000 women
and year (all ages).
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Age-specific incidence rates of cervical cancer in the sub-Saharan Africa region, and less or
more developed regions. Data source: GLOBOCAN 2008 [2].
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Estimated number of new cases of cervical cancer in the sub-Saharan Africa region by age
groups, in 2008, and projected in 2030. Data source: GLOBOCAN 2008 [2].
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Estimated years of life lost in 2008: (a) for cervical cancer by regions (b) for the sub-
Saharan Africa region by type of cancer. Data from Saint Helena, Säo Tomé and Principe,
Seychelles and South Sudan were unavailable in GLOBOCAN 2008 [2]. EMENA:
Extended Middle East and North Africa; LAC: Latin America and Caribbean; N America:
North America; NHL: Non-Hodgkin Lymphoma; Oceania incl. Aus. & NZ: Oceania
including Australia and New Zealand; SSA: Sub-Saharan Africa.
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Table 2
Trends in incidence of cervical cancer in selected cancer registries.
Cancer registry N cases Crude Rate ASR
Mali, Bamako
Vol 6 - 1987–1989 124 12.2 23.4
Vol 7 - 1988–1992 248 14.8 29.1
Vol 8 - 1994–1996 182 15.9 35.9
Uganda, Kyadondo (Kampala)
Vol 7 - 1991–1993 248 15.6 40.8
Vol 8 - 1993–1997 465 16.1 41.7
Vol 9 - 1998–2002 649 16.4 45.8
Zimbabwe, Harare
Vol 7 - 1990–1992 295 19.5 64.8
Vol 8 - 1993–1997 613 19.1 55.0
Vol 9 - 1998–2002 818 18.8 47.3
ASR: age-standardized incidence rate, per 100,000 women and year (all ages); N: number.
Data source: Cancer Incidence in Five Continents [3].
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Table 5
Incidence of vulvar, vaginal, penile and anal cancer in selected cancer registries during 1998–2002.
Cancer N cases Crude Rate ASR
Vulvar cancer
Uganda, Kyadondo County 7 0.2 0.3
Zimbabwe, Harare 16 0.4 0.7
Vaginal cancer
Uganda, Kyadondo County 6 0.2 0.6
Zimbabwe, Harare 6 0.1 0.3
Penile cancer
Uganda, Kyadondo County 25 0.7 2.8
Zimbabwe, Harare 19 0.4 0.9
Anal cancer, Women
Uganda, Kyadondo County 3 <0.1 <0.1
Zimbabwe, Harare 2 <0.1 <0.1
Anal cancer, Men
Uganda, Kyadondo County 2 <0.1 0.2
Zimbabwe, Harare 4 <0.1 0.2
ASR: Age-standardized incidence rate, per 100,000 women and year (all ages); N: number.
Data source: Cancer Incidence in Five Continents [3].
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